Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vertex board adds former HHS official

Executive Summary

Vertex will nominate former HHS Assistant Secretary for Health Eve Slater, MD, to board of directors at annual meeting May 6. Slater served at HHS for a year after a 19-year career at Merck. She left HHS in February 2003 (1"The Pink Sheet" July 28, 2003, In Brief). Vertex also plans to nominate former Pfizer President-Global R&D John Niblack, PhD, to board. Niblack retired from Pfizer in 2002 (2"The Pink Sheet" Oct. 27, 2003, p. 20)...

You may also be interested in...

Pfizer Names LaMattina To Head R&D; Licensing Is “Corr” Function

Pfizer Global R&D President John LaMattina, PhD, will attempt to enhance the productivity of the largest pharmaceutical research operation in the world

President nominates HHS assistant secretaries

President Bush nominates HHS Principal Deputy Assistant Secretary Cristina Beato to be assistant secretary for health July 23. Beato would replace U.S. Surgeon General Richard Carmona, MD, who has been acting assistant secretary since Eve Slater, MD, resigned in February ("The Pink Sheet" Feb. 10, 2003, p. 10). Administration also names Senate Joint Economic Committee Senior Health Economist Michael O'Grady, PhD, to be HHS assistant secretary for planning & evaluation. O'Grady would replace former ASPE Bobby Jindal (1"The Pink Sheet" Feb. 17, 2003, In Brief)...

Does Polivy Provide A Cure For DLBCL? Too Early To Say, Argue NICE Experts

Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts